How Long Does Semaglutide & Tirzepatide Stay In Your System?

Three thousand patients a month type “how long does semaglutide stay in your system” or the equivalent question for tirzepatide into Google. The honest answer comes directly from the FDA labels: semaglutide's elimination half-life is about 1 week (around 168 hours)^[1] and tirzepatide's is about 5 days^[4]. The standard pharmacokinetic threshold for “fully out of the body” is five half-lives — about 5 weeks for semaglutide and about 25 days for tirzepatide. Orforglipron (Foundayo), the new oral GLP-1, clears far faster — about 6 days — because its half-life is only 29-49 hours^[6].

Quick answer: half-life and washout for every GLP-1

These are population-average values from the FDA prescribing information for each drug. Individual clearance varies with kidney function, body weight, and (for tirzepatide) the depth and consistency of subcutaneous absorption. For personalized math, use our GLP-1 washout calculator.

What “in your system” actually means

The phrase “how long does it stay in your system” can mean three different things, and the answer depends on which one you actually care about:

• Half-life (t½) — the time it takes for the drug concentration in plasma to fall by 50%. This is the single most-cited pharmacokinetic number and the one that appears in Section 12.3 of every FDA label. For semaglutide it is about 1 week^[1]; for tirzepatide, about 5 days^[4].
• Steady state — the point at which the amount of drug entering the body each week equals the amount being eliminated, so plasma concentrations stabilize. This is reached after roughly 4-5 half-lives of consistent dosing. For semaglutide, that's 4-5 weeks of weekly injections^[1]; for tirzepatide, about 4 weeks^[4]. This is why your prescriber waits 4 weeks at each dose before titrating up.
• Full washout (5 half-lives) — the standard pharmacokinetic convention that more than 97% of a drug has been eliminated after 5 half-lives, which is treated as “effectively out of the body” for clinical decision-making. For semaglutide, that's about 5 weeks; for tirzepatide, about 25 days; for orforglipron, about 6 days^[6].

When patients ask “how long does it stay,” they usually mean the third one — full washout. That is the timeline that matters for pregnancy planning, surgery scheduling, and waiting out side effects. The rest of this article uses the five-half-life convention.

Semaglutide pharmacokinetics deep-dive

Semaglutide's elimination half-life is approximately 1 week (about 168 hours) in adults, per the FDA Wegovy prescribing information^[1]. The same value appears in the Ozempic label^[2] (Ozempic and Wegovy are the same molecule at different dose strengths) and in the Rybelsus label for the oral formulation^[3].

Steady state is reached after about 4-5 weeks of weekly dosing^[1]. This is why titration schedules always wait at least 4 weeks at each dose before stepping up — anything faster means you are titrating against a drug that has not yet reached its full effect, which both understates the effective dose and overstates short-term side-effect tolerance.

Apply the five-half-life rule and a single dose of semaglutide is more than 97% eliminated about 5 weeks after the injection. After a long course of weekly dosing, the same 5-week window starts from the day of the final dose. This is the basis for the FDA's instruction in the Wegovy label that women of childbearing potential should discontinue semaglutide at least 2 months before a planned pregnancy^[1] — a deliberately conservative buffer beyond the 5-week washout to account for individual variability.

Oral semaglutide (Rybelsus) has the same systemic half-life as the injectable, despite being absorbed through the stomach lining via an absorption enhancer (SNAC)^[3]. Once it's in the bloodstream, the molecule is identical, so the elimination kinetics are the same. The difference is bioavailability, not half-life.

Tirzepatide pharmacokinetics deep-dive

Tirzepatide's elimination half-life is approximately 5 days, per the FDA Zepbound prescribing information^[4]. The same value appears in the Mounjaro label^[5] (Mounjaro and Zepbound are the same molecule at different approved indications). Steady state is reached after about 4 weeks of weekly dosing^[4].

Apply the five-half-life rule and a tirzepatide dose is more than 97% eliminated about 25 days after the injection. For pregnancy planning, the FDA Zepbound label echoes the same 2-month pre-conception window that applies to semaglutide^[4] — again, a buffer beyond the strict pharmacokinetic washout.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both receptor activities are tied to the same molecule, so there is one half-life for both pharmacological actions. You do not need to think about “GIP washout” and “GLP-1 washout” separately.

Orforglipron (Foundayo) — much shorter, because it's oral

Orforglipron, FDA-approved as Foundayo on April 1, 2026, is a fundamentally different molecule from semaglutide and tirzepatide. It's a small-molecule, non-peptide GLP-1 receptor agonist that can be taken orally without an absorption enhancer^[6]. Because it lacks the fatty-acid albumin-binding chain that gives semaglutide and tirzepatide their week-long half-lives, orforglipron clears much faster: its elimination half-life is approximately 29-49 hours per the FDA Foundayo label^[6].

That gives a five-half-life washout of roughly 6-10 days from the last dose. Steady state on a once-daily oral dose is reached within about a week^[6]. The practical consequence: if you stop Foundayo for any reason — pregnancy, surgery, intolerance — the washout window is far shorter than for any injectable GLP-1. For a full provider list and the access landscape, see our Foundayo provider directory.

Why the long half-life is engineered, not accidental

Native GLP-1 — the hormone your gut secretes after a meal — has a half-life of about 2 minutes. The enzyme DPP-4 degrades it almost the instant it enters circulation. That short half-life is great for the physiological role of GLP-1 (a transient post-meal signal) but makes the native molecule completely unworkable as a drug.

Semaglutide solves this problem with two independent engineering modifications that are often conflated but do separate jobs:

1. An α-aminoisobutyric acid (Aib) substitution at position 8 of the peptide backbone. The Aib substitution sterically blocks the DPP-4 cleavage site and gives the molecule its DPP-4 resistance. Without this, semaglutide would still be degraded in roughly the same 2 minutes as native GLP-1.
2. A C18 fatty diacid (γGlu-2xOEG linker) attached at Lys-26. The fatty diacid binds reversibly and tightly to circulating albumin (greater than 99% plasma protein binding). Albumin is too large to be filtered by the kidney, so the bound peptide is shielded from renal clearance. This is what produces the multi-day, not the DPP-4 protection.

Tirzepatide uses the same general strategy but with a different fatty acid linker — a C20 fatty diacid attached to a Lys residue — which gives slightly different albumin-binding kinetics and the somewhat shorter ~5-day half-life compared with semaglutide's ~7-day half-life^[1][4].

Subcutaneous injection adds a second slow-release layer: the drug forms a depot in the subcutaneous tissue and is released gradually into the bloodstream. The combination of subcutaneous depot release and albumin binding is what produces the smooth, week-long pharmacokinetic profile that makes once-weekly dosing possible^[1].

Orforglipron does not use this trick — it is a small molecule that does not bind albumin and is cleared by the usual hepatic and renal pathways^[6]. That is why the same drug class can have a 1-week half-life (semaglutide) or a 30-hour half-life (orforglipron), depending on the molecular engineering.

What “out of your system” means in practice

Pregnancy planning

The FDA Wegovy and Zepbound labels both instruct that women of childbearing potential should discontinue the drug at least 2 months before a planned pregnancy^[1][4]. This is longer than the strict five-half-life washout (5 weeks for sema, 25 days for tirz) on purpose: it adds a buffer for individual clearance variation and gives the body extra time to normalize before conception. For deeper coverage of GLP-1s, fertility, and the full reproductive picture, see our GLP-1, pregnancy, PCOS, and fertility article.

Surgery

The American Society of Anesthesiologists has issued consensus guidance on stopping GLP-1s before surgery to reduce the risk of pulmonary aspiration from delayed gastric emptying^[7]. The guidance is to hold the drug for at least 1 week before surgery for weekly injectable GLP-1s and at least 24 hours for daily oral GLP-1s. This is much shorter than the full five-half-life washout because the goal is to reduce gastric retention to a clinically acceptable level, not to fully eliminate the drug. For the full preoperative protocol, see our GLP-1 surgery and anesthesia ASA guidance article.

Side-effect resolution

Drug elimination and side-effect resolution are not the same timeline. Even after the molecule is gone, the physiological systems it affected — gastric emptying rate, appetite signaling, glucose homeostasis — take additional time to renormalize. Most patients report GI side effects (nausea, early satiety, constipation) resolving within 4-8 weeks after the last dose, even though semaglutide itself is biochemically gone in 5 weeks. For the full picture of what to expect after stopping, see our articles on what happens when you stop semaglutide and how to taper off GLP-1 safely.

Why side effects can persist after the drug is gone

The most common reason for symptoms outlasting the drug is gastric emptying. GLP-1s slow gastric emptying by acting on vagal afferents and on the gastric smooth muscle directly. With long exposure, the gastric motility setpoint adapts. When the drug is withdrawn, the receptor signaling stops within the half-life window — but the gastric motility machinery does not snap back instantly. Most patients see full normalization within 4-8 weeks of the last dose.

A second mechanism is appetite signaling. GLP-1 receptors in the hypothalamus influence satiety and reward circuits. When dosing stops, ghrelin and leptin signaling shift back toward baseline over weeks, not days. The most-reported post-stop experience is the return of food noise and hunger before the body weight has changed — the appetite system reactivates faster than the body can rebound.

A third mechanism is the weight-loss-related downstream effects: blood pressure, blood glucose, lipid panel, and liver enzymes generally improve in proportion to weight loss, and they regress in proportion to weight regain. That timeline is months, not weeks, and it is independent of the drug clearance curve.

Personalized washout: use the calculator

Population-average half-lives are useful for orientation, but the actual clearance for a specific patient depends on kidney function, body weight, dose, and whether they were at steady state. For personalized math — pick your drug, your last dose date, and your dose, and get the calculated plasma concentration and washout window — use our GLP-1 washout calculator. It implements the standard one-compartment elimination model with the FDA-label half-life values from this article.

Frequently asked questions

Can semaglutide or tirzepatide be detected on a drug test?

No. GLP-1 receptor agonists are not on standard SAMHSA-5 or extended workplace drug screening panels, and there is no commercial drug test for semaglutide or tirzepatide. Specialized LC-MS/MS assays exist in research and anti-doping contexts (the World Anti-Doping Agency does not currently prohibit GLP-1s), but they are not part of any routine clinical or employer drug screen. If you are worried about an upcoming drug test, GLP-1s will not show up on it.

Does semaglutide get stored in body fat?

No. Semaglutide is a peptide that binds tightly to albumin in the bloodstream — that is the engineering trick that gives it its 1-week half-life^[1]. It is not lipophilic the way THC, some psychiatric drugs, or long-acting depot anesthetics are. Once dosing stops, it is cleared on the predictable half-life schedule from the FDA label, with no fat-tissue reservoir to slowly leach back into circulation.

How long after stopping does the nausea go away?

For most patients, GI side effects resolve within 4-8 weeks of the last dose. The drug itself is mostly gone in 5 weeks for semaglutide and 25 days for tirzepatide, but gastric emptying takes additional time to normalize. If GI symptoms persist beyond 8 weeks after stopping, that usually points to something other than residual GLP-1 effect — talk to your prescriber.

How long before pregnancy should I stop?

At least 2 months before a planned conception, per the FDA Wegovy and Zepbound labels^[1][4]. This is longer than the strict five-half-life washout (5 weeks for semaglutide, 25 days for tirzepatide) and includes a deliberate buffer for individual clearance variation. Discuss the timing with your obstetrician — the buffer also gives time to restart any chronic medications that were paused on the GLP-1 and to optimize weight, blood pressure, and glycemic control before conception.

Why is the half-life so long?

Native GLP-1 has a half-life of about 2 minutes because the DPP-4 enzyme degrades it almost instantly. Semaglutide and tirzepatide were engineered with a fatty-acid side chain that binds reversibly to albumin, which protects them from DPP-4 and slows kidney clearance. That, combined with the slow-release subcutaneous depot from once-weekly injection, gives both drugs week-long pharmacokinetic profiles that make weekly dosing possible^[1][4]. Orforglipron does not use this strategy and clears in about a day^[6].

What about Rybelsus (oral semaglutide) — is the half-life shorter?

No. Oral semaglutide is the same molecule as injectable semaglutide, just packaged with an absorption enhancer (SNAC) that gets a small fraction of the dose across the stomach lining^[3]. Once it's in the bloodstream, the elimination kinetics are identical to injectable semaglutide — about a 1-week half-life. The difference between Rybelsus and Wegovy/Ozempic is bioavailability and dose size, not how long the drug stays in your system once it's absorbed.

Bottom line

• Semaglutide has a half-life of about 1 week and clears in about 5 weeks (five half-lives), per the FDA Wegovy label^[1].
• Tirzepatide has a half-life of about 5 days and clears in about 25 days, per the FDA Zepbound label^[4].
• Orforglipron (Foundayo, oral) has a half-life of 29-49 hours and clears in about 6-10 days^[6].
• The FDA tells women to stop sema and tirz at least 2 months before pregnancy^[1][4] — a deliberate buffer beyond the strict pharmacokinetic washout.
• GI side effects usually take 4-8 weeks to resolve after stopping, even though the drug is biochemically gone earlier — gastric emptying takes time to renormalize.
• GLP-1s are not on any routine drug screening panel and there is no commercial test for them.
• The long half-life is engineered, not accidental: a fatty-acid side chain on the peptide binds reversibly to albumin and protects it from DPP-4 degradation.

Related research and tools

• GLP-1 washout calculator — personalized half-life math for any drug, dose, and last-dose date
• GLP-1 surgery and anesthesia: the ASA guidance — full preoperative hold protocol
• What happens when you stop semaglutide — the rebound timeline and what to expect
• How to taper off a GLP-1 safely — step-down dosing and lifestyle bridge
• GLP-1, pregnancy, PCOS, and fertility — full reproductive-health picture

Important disclaimer. This article is educational and does not constitute medical advice. The pharmacokinetic values cited here are population averages from the FDA prescribing information for each drug; individual clearance varies with kidney function, body weight, dose, and other factors. Decisions about stopping a GLP-1 before pregnancy, surgery, or any other clinical event should always involve the prescribing clinician and the relevant specialist (obstetrician, anesthesiologist, etc.). Do not stop a prescribed medication based on a web article.